What GLP-1 Marketing Reveals About Concierge Medicine's Opportunity
A year of compounded GLP-1 through telehealth and a year of concierge membership cost about the same. One manages a prescription; one manages a relationship. What that overlap means, accurately stated.
Updated November 2026: redesigned. Corrected: FDA warning-letter totals (the "55+ since September 2025" figure was replaced with the documented September 2025, March 2026 and June 2026 waves); persistence figures now cite Prime Therapeutics directly. Removed: an Editor-in-Chief quote saying almost no GLP-1 spending has a physician attached, because KFF data show 76% of users got the drug from their own doctor; unverified TV ad-spend figures; an unverified concierge fee mean. Added: KFF data on where patients get GLP-1s and the JAMA secret-shopper study.
Start here: the questions this brief answers
Patients already pay out of pocket for health outcomes, and the 50-to-64 age group leads GLP-1 use, which overlaps concierge medicine's core market. Most GLP-1 users get the drug from their own doctor; the oversight concerns center on online sellers. Concierge medicine's opportunity is to be the continuing physician relationship around any treatment, marketed compliantly and never as a treatment alternative.
Do GLP-1s and concierge really cost the same?
A year of compounded cash-pay GLP-1 runs roughly $1,800 to $5,400; the 2026 concierge median is $3,200. Go to the full answer ↓
Why is GLP-1 marketing so effective?
It runs as an acquisition system, and parts of it have drawn FDA warning letters. Go to the full answer ↓
Who uses GLP-1s?
Use peaks at 22% among adults 50 to 64. Go to the full answer ↓
Do GLP-1 patients have a doctor involved?
Most do: 76% got it from their own doctor. Online sellers raise the oversight concerns. Go to the full answer ↓
How should concierge practices market around this?
As the trusted physician relationship, never as a treatment alternative. See the compliance check. Go to the full answer ↓
Part 1 · The setup
Patients already pay out of pocket for a health outcome
A year of compounded GLP-1 through a cash-pay telehealth program and a year of concierge membership now cost roughly the same. The open question is which model earns that money, and why.
This is market and editorial analysis, not medical, legal or financial advice. It does not evaluate the clinical merits of GLP-1 medications. Concierge medicine is not, and should never be marketed as, a treatment alternative to any medication.
Part 2 · What patients pay
A year of each model, side by side
Approximate annual cost to a patient
Industry ResearchSources: list prices reported by the Washington Examiner, citing KFF1; a commercial telehealth price tracker2; CMT 2026 Industry Pricing Benchmark.3 Bars use the midpoint of each range. Most GLP-1 users have some insurance coverage, so these are not typical out-of-pocket costs.
Direct primary care · a different model · HSA rules
Since January 1, 2026, qualifying DPC arrangements at or below $150 a month for an individual ($300 for a family) no longer disqualify a patient from an HSA, and HSA funds can pay the fee.5
This describes DPC, not concierge medicine, and is shown separately for context only. Not tax advice.
Part 3 · Why GLP-1 marketing wins attention
Acquisition systems, and the regulatory pullback
Telehealth GLP-1 companies built acquisition systems, not just ads. One marketing agency estimates it costs $150 to $250 to acquire a paying GLP-1 telehealth patient, who may be worth $600 to $2,000 over the subscription.6 Those are agency estimates, not audited figures.
Much of that marketing has drawn federal scrutiny. The FDA sent 30 warning letters to telehealth companies marketing compounded GLP-1s on March 3, 2026,7 and 25 more in June 2026, following a larger September 2025 wave aimed at direct-to-consumer drug marketing.8 The letters allege the marketing implied compounded products were FDA-approved or equivalent to branded drugs.
About 80 warning letters and 40 untitled letters on direct-to-consumer drug marketing, many involving compounded GLP-1s.8
30 warning letters to telehealth companies marketing compounded GLP-1s.7
25 more warning letters, plus an FDA webpage on telehealth compliance pitfalls.8
Warning letters are allegations, not findings of wrongdoing, and this is not a claim that GLP-1 medications are unsafe. It is a factual account of public enforcement, reported as any trade publication would.
Part 4 · The demographic overlap
The same age group is paying for both
Adults currently taking a GLP-1, by age (late 2025)
Population DataSource: KFF Health Tracking Poll, 1,350 adults, October 27 to November 2, 2025.4 Lower use at 65+ likely reflects Medicare's exclusion of weight-loss drugs.
A 2026 directory report estimates about two-thirds of concierge patients are 55 or older.9 That figure is industry-reported and its method isn't published, but if it holds, the 50-to-64-year-old patient already paying for a GLP-1 sits inside concierge medicine's core market. The opportunity is not to replace any treatment. It is to be the physician relationship around it.
Part 5 · The honest part
Who is attached to the prescription?
Most GLP-1 patients do have a physician involved: 76% of users said they got the drug from one of their own doctors, while 17% used an online provider and 9% a medical spa.4 The concern is concentrated in that online segment. A JAMA secret-shopper study found 45 of 49 online sellers (91.8%) issued a prescription to a simulated patient, about two-thirds with no clinician interaction.10 A KFF Health News investigation documented patients harmed after dosing instructions from telehealth providers.11
Where GLP-1 users got their prescription (late 2025)
Population DataSource: KFF, 2025.4 Respondents could choose more than one, so totals exceed 100%.
one-year persistence on obesity GLP-1s, 2021 starters vs Q1 2024 starters, as supply shortages eased.12
Industry Researchfor weight to return to baseline after stopping semaglutide or tirzepatide, on average.13
Clinical Trial EvidenceContinuity matters after the prescription too. Persistence has improved sharply as shortages resolved,12 but a 2026 meta-analysis in The BMJ found that weight returns toward baseline after stopping weight-management drugs, and faster than after behavioral programs.13 The authors framed obesity as a chronic condition that needs long-term management.
The question for concierge medicine is not whether patients will pay. They already do. It is whether a physician who knows the patient is part of the plan: adjusting doses, catching interactions, and planning for what happens if the medication stops.
Part 6 · The marketing playbook
Four moves, done compliantly
Lead with the problem, not the amenity list
Name what fails in a 15-minute visit before listing same-day access or longer visits.
Build a system, not a campaign
Educational content, a low-friction next step and a referral system that runs consistently.
Be the trusted second opinion
Position the practice as the place for an unhurried conversation about any treatment a patient is considering, never as a treatment alternative.
Say what you're for to physicians on the fence
Patients are already paying out of pocket for health outcomes, and HSA rules changed for qualifying DPC in 2026.5
Compliance check before you publish GLP-1-adjacent marketing
0 complete
Nothing you check is saved or sent anywhere. Educational self-review only.
Learn → Build → Lead
Putting it to work
Patients already pay for outcomes; what they often lack is continuity.
Run the compliance check on every campaign before it goes live.
Be the physician relationship around any treatment, never the treatment alternative.
Methods, limitations and evidence types
How this brief was built
CMT re-verified the original August 2026 brief's figures against primary sources where possible. Pricing figures from commercial trackers and agencies are labeled Industry Research. The original brief cited several marketing blogs; CMT kept only figures that are labeled and plausible for context and removed the rest. DPC appears only in the dashed box.
Every key finding is labeled by evidence type. Labels describe the type of evidence, not its value. Each type answers different questions. Funding is disclosed on every source.
What we don't know
- The CMT 2026 Industry Pricing Benchmark's method and sample size are not published in this brief.
- Telehealth GLP-1 prices change weekly.
- The concierge patient age share comes from a directory report with an unpublished method.
- No study compares outcomes of GLP-1 patients managed in concierge practices with those managed elsewhere.
How to cite this brief
Concierge Medicine Today. What GLP-1 Marketing Reveals About Concierge Medicine's Opportunity. CMT Research Brief No. 11, Version 2.0. November 2026. conciergemedicinetoday.net.
External review: This brief has not been externally peer reviewed. Corrections: CMT corrects factual errors promptly and notes the change in the updates line. Send corrections through conciergemedicinetoday.net/contact.
Keep reading
Related CMT Research Briefs
References
Sources and citations
- Washington Examiner. One in 8 adults has used Ozempic or similar GLP-1 drugs. November 2025. Reports U.S. list prices of $936 to $1,349 a month before insurance or discounts. washingtonexaminer.comEvidence type: Practice Insight · Funding: not stated (news report)
- glpchart.com. GLP-1 Telehealth Price Report 2026. Weekly cash-pay price tracker; not peer-reviewed.Evidence type: Industry Research · Funding: not stated (commercial price tracker)
- Concierge Medicine Today. 2026 Industry Pricing Benchmark. Median, year-over-year change and range as cited by third-party pricing guides (Haute MD, Mezzi), 2026. Method not published. hauteliving.comEvidence type: Industry Research · Funding: Concierge Medicine Today (self-conducted; no outside funder)
- KFF Health Tracking Poll: Prescription drug costs, views on Trump administration actions, and GLP-1 use. November 14, 2025. 1,350 adults, October 27 to November 2, 2025; ±3 points. kff.orgEvidence type: Population Data · Funding: not stated (designed and analyzed by KFF)
- Internal Revenue Service. Notice 2026-5, Expanded availability of health savings accounts under the One, Big, Beautiful Bill Act. December 2025. irs.govEvidence type: Policy and Law · Funding: federal (IRS)
- ClinicAds. Telehealth marketing in 2026: the complete guide to compliant, profitable patient acquisition. July 17, 2026. Agency estimates; not peer-reviewed.Evidence type: Industry Research · Funding: not stated (marketing agency guide)
- Foley & Lardner. GLP-1 compliance: FDA targets telehealth marketing in 30 new warning letters. March 2026. Letters sent March 3, 2026. foley.comEvidence type: Policy and Law · Funding: not stated (law firm analysis of FDA letters)
- Sheppard Mullin. FDA's focus returns to compounding and telehealth: another wave of warning letters. June 18, 2026. Counts September 2025 (about 80 warning and 40 untitled letters across direct-to-consumer drug marketing), March 2026 (30) and June 2026 (25). sheppard.comEvidence type: Policy and Law · Funding: not stated (law firm analysis of FDA letters)
- Concierge MD Finder. U.S. Concierge Medicine Market Report 2026. May 30, 2026. Patient age share as reported; method not published. CMT could not confirm a working link.Evidence type: Industry Research · Funding: not stated (commercial directory report)
- Chetty AK, Chen AS, Ross JS, Ramachandran R. Online prescribing of GLP-1 receptor agonists: a secret shopper study. JAMA. Published online July 6, 2026. doi:10.1001/jama.2026.9131. Summary via AJMC and HCPLive. ajmc.comEvidence type: Practice Insight · Funding: not stated (check article)
- Sausser L, Rosenfeld M. Telehealth booms as demand for GLP-1s surges and questions mount about safety, oversight. KFF Health News. June 2026. alaskabeacon.comEvidence type: Practice Insight · Funding: not stated (news investigation, KFF Health News)
- Prime Therapeutics. GLP-1 therapy to treat obesity among members without diabetes: three-year persistence. 2025. Commercial claims; one-year persistence by start year, 2021 to Q1 2024. primetherapeutics.comEvidence type: Industry Research · Funding: industry (Prime Therapeutics, a pharmacy benefit manager; self-conducted)
- West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. 37 studies, 9,341 adults. phc.ox.ac.ukEvidence type: Clinical Trial Evidence · Funding: federal (UK National Institute for Health and Care Research), per University of Oxford
Disclaimer
This brief is educational and informational only. It is not medical, legal, tax, financial or accounting advice, and it is not media training or a substitute for advice from a qualified professional. Concierge Medicine Today is an independent trade publication: no organization paid for favorable coverage, no practice model is favored, and funding is disclosed for every source cited. Product, company and organization names are used for identification and context only and do not imply endorsement. While we work to be accurate, this content is not without possible error or omission. © 2007-2026 Concierge Medicine Today, LLC. All rights reserved.
Concierge Medicine Today · independent trade publication since 2007 · Learn → Build → Lead

